Potency of Δ9–tetrahydrocannabinol and other cannabinoids in cannabis in England in 2016: Implications for public health and pharmacology

Drug Testing and Analysis

Volumn 10, Issue 4, 2018, Pages 628-635

  Potter, David J ^a   Hammond, Kathy ^a   Tuffnell, Shaun ^a   Walker, Christopher ^b   Di Forti, Marta ^b  

^a Porton Down Science Park   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

cannabidiol; cannabinoid; potency; psychosis; 9 tetrahydrocannabinol

Indexed keywords

GAS CHROMATOGRAPHY; PUBLIC HEALTH;

CANNABIDIOL; CANNABINOIDS; ENGLAND; HEALTH CONCERNS; HIGH POTENCY; POTENCY; PSYCHOSIS; RESIN SAMPLES; UNITED KINGDOM; Δ9-TETRAHYDROCANNABINOL;

RESINS;

CANNABIS; DRONABINOL; RESIN; CANNABIDIOL; CANNABINOID; PSYCHOTROPIC AGENT; STREET DRUG;

ARTICLE; CANNABIS USE; COMPARATIVE STUDY; DECARBOXYLATION; DRUG MARKETING; DRUG POTENCY; ENGLAND; GAS CHROMATOGRAPHY; NONHUMAN; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; TRADITIONAL MEDICINE; CHEMISTRY; HUMAN; PUBLIC HEALTH;

CANNABIDIOL; CANNABINOIDS; CANNABIS; CHROMATOGRAPHY, GAS; DRONABINOL; ENGLAND; HUMANS; PSYCHOTROPIC DRUGS; PUBLIC HEALTH; STREET DRUGS;

EID: 85042545022     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.2368     Document Type: Article

References (39)

1. Hargreaves J, Smith K, eds. Home Office National Statistics, Seizures of Drugs in England and Wales, Financial Year Ending 31 March 2016. Statistical Bulletin 13/16. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/564412/seizures-drugs-hosb1316.pdf. Accessed July 24, 2017
2. Henquet C, Krabbendam L, Spauwen J, et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ. 2004;330:11.
3. Moore THM, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370:319-328.
4. Di Forti M, Morgan C, Dazzan P, et al. High-potency cannabis and the risk of psychosis. Br J Psychiatry. 2009;195:488-491. https://doi.org/10.1192/bjp.bp.109.064220
5. Large M, Sharma S, Compton MT, Slade T, Nielssen O. Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Arch Gen Psychiatry. 2011;68:555-561. https://doi.org/10.1001/archgenpsychiatry.2011
6. Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E. Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull. 2016;42:1262-1269. https://doi.org/10.1093/schbul/sbw003
7. United Nations Office on Drugs and Crime. Cannabis: Why we should care. In: United Nations Office on Drugs and Crime. 2006 World Drug Report. Vol.2 New York, NY: United Nations Publications; 2006:155-199.
8. European Monitoring Centre on Drugs and Drugs Addiction. European Drug Report: Trends and Developments. Luxembourg: Publications Office of the European Union; 2016. https://doi.org/10.2810/04312.
9. Potter DJ, Clark P, Brown MB. Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. J Forensic Sci. 2008;53:90-94.
10. Potter DJ. The propagation, characterisation and optimisation of Cannabis sativa L as a phytopharmaceutical [thesis]. London UK: King's College London; 2009:76–78. https://www.scribd.com/document/45314251/Potter-Thesis-2009. Accessed January 22, 2018.
11. Hardwick S, King LA. Home Office Cannabis Potency Study. London, UK: Home Office Scientific Development Branch; 2008:2008.
12. Chouvy PA. The Supply of Hashish to Europe [Report prepared for European Monitoring Centre on Drugs and Drug Addiction 13 July 2015]. http://www.emcdda.europa.eu/system/files/publications/2373/downloads/EDRM2016%20Background%20paper_CHOUVY_The%20Supply%20of%20Hashish%20to%20Europe.pdf. Accessed July 24, 2017.
13. Dujourdy L, Besacier F. A study of cannabis potency in France over a 25 years period (1992–2016). Forensic Sci Int. 2017;272:72-80.
14. British Medical Association. Therapeutic Uses of Cannabis. Oxfordshire, UK: CRC Press; 1997.
15. House of Lords Select Committee on Science and Technology. Cannabis the Scientific and Medical Evidence [HL Paper 151-I]. London, UK: The Stationery Office; 1998.
16. Medicines and Healthcare Products Regulatory Agency. 2015 Sativex Oromucosal Spray: Summary of Product Characteristics. http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1492496184557.pdf. Accessed July 24, 2017.
17. National Institute for Health and Care Excellence (NICE). Multiple sclerosis: management of multiple sclerosis in primary and secondary care [CG186]. https://www.nice.org.uk/guidance/cg186/resources. Accessed January 22, 2018.
18. Barnes M, Barnes J. Cannabis: The Evidence for Medical Use. https://drive.google.com/file/d/0B0c_8hkDJu0DUDZMUzhoY1RqMG8/view. Accessed July 24, 2017.
19. All-Party Parliamentary Group for Drug Policy Reform. Access to Medicinal Cannabis: Meeting Patient Needs [Inquiry Report]. London, UK: All-Party Parliamentary Group for Drug Policy Reform; 2016:21–24. https://drive.google.com/file/d/0B0c_8hkDJu0DRnBfdGRDRXBROUU/view. Accessed July 24, 2017.
20. United Nations Office on Drugs and Crime. Changing the perception of cannabis. In: World Drug Report 2015. Vienna, Austria: United Nations Office of Drugs and Crime;2015:76. https://www.unodc.org/documents/wdr2015/World_Drug_Report_2015.pdf. Accessed July 24, 2017.
21. Mahlberg PG, Hammond CT, Turner JC, Hemphill JK. Structure, development and composition of glandular trichomes of Cannabis sativa L. In: Rodriguez EP, Healey L, Mehta I, eds. Biology and Chemistry of Plant Trichomes. London, UK: Plenum Press; 1984:23-51.
22. United Nations Office on Drugs and Crime. Recommended Methods for the Identification and Analysis of Cannabis and Cannabis Products. NY, New York: United Nations; 2009. https://www.unodc.org/documents/scientific/ST-NAR-40-Ebook.pdf. Accessed July 24, 2017.
23. Englund A, Freeman TP, Murray RM, McGuire P. Can we make cannabis safer? Lancet Psychiatry. https://doi.org/10.1016/S2215-0366(17)30075-5.
24. European Monitoring Centre on Drugs and Drugs Addiction. EMCDDA Insights: An Overview of Cannabis Potency in Europe. Luxembourg: Publications Office of the European Union, 2004. http://www.emcdda.europa.eu/attachements.cfm/att_33985_EN_Insight6.pdf. Accessed July 24, 2017.
25. Small E. Cannabis: A Complete Guide. Oxfordshire, UK: CRC Press; 2016:260.
26. Mwenda L, Ahmad M, Kumari K. Seizures on Drugs in England and Wales, 2003 [Findings 265]. London, UK: Home Office Research, Development and Statistics Directorate, Office for National Statistics; 2005.
27. de Meijer EPM, Bagatta M, Carboni A, et al. The inheritance of chemical phenotype in Cannabis sativa L. Genetics. 2003;163:335-346.
28. European Monitoring Centre on Drugs and Drugs Addiction. Cannabis Production and Markets in Europe [EMCDDA Insights 12]. Lisbon, Portugal: EMCDDA; 2012. http://www.emcdda.europa.eu/publications/insights/cannabis-market. Accessed July 24, 2017.
29. Niesink RJ, Rigter S, Koeter MW, Brunt TM. Potency trends of Δ9-tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005-15. Addiction. 2015;110:1941-1950. https://doi.org/10.1111/add.13082
30. Chouvy PA, Afsahi K. Hashish revival in Morocco. Int J Drug Policy. 2014;25:416-423.
31. Martone G, Della CE. Analysis of the ageing processes in hashish samples from different geographic origin. Forensic Sci Int. 1990;47:147-155.
32. Pertwee RG, Gascio MG. Known pharmacological actions of delta-9-tetrahydrocannabinol and of four other chemical constituents of cannabis that activate cannabinoid receptors. In: Pertwee R, ed. Handbook of Cannabis. Oxford, UK: Oxford University Press; 2014:115–136.
33. Gascio MG, Pertwee RG. Kohn pharmacological actions of nine nonpsychotropic phytocannabinoids. In: Pertwee R, ed. Handbook of Cannabis. Oxford, UK: Oxford University Press; 2014:137–156.
34. Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163:1344-1364. https://doi.org/10.1111/j.1476-5381.2011.01238.x
35. Di Forti M, Marconi A, Carra E, et al. Proportion of patients in South London with first episode psychosis attributable to use of high potency cannabis. Lancet Psychiatry. 2015;2(3):233-238.
36. Murray RM, Quigley H, Quattrone D, Englund A, Di Forti M. Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis. World Psychiatry. 2016;15(3):195-204.
37. Freeman TP, Morgan CJ, Hindocha C, Schafer G, Das RK, Curran HV. Just say ‘know’: How do cannabinoid concentrations influence users’ estimates of cannabis potency and the amount they roll in joints? Addiction. 2014;109:1686-1694.
38. Casadio P, Fernandes C, Murray RM, Di Forti M. Cannabis use in young people: the risk for schizophrenia. Neurosci Biobehav. 2011;35:1779-1787.
39. Hasin DS, Sarvet AL, Cerdá M, et al. US adult illicit cannabis use, cannabis use disorder, and medical marijuana laws: 1991-1992 to 2012-2013. JAMA Psychiat. 2017;74(6):579-588. https://doi.org/10.1001/jamapsychiatry.2017.0724